Prognostic factors and survival in metastatic breast cancer: A single institution experience
- 1 May 2013
- journal article
- review article
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 18 (3) , 127-132
Abstract
The current retrospective study aims to identify some determinants of survival in metastatic breast cancer. The study concerned 332 patients with synchronous (SM) or metachronous (MM) metastatic breast cancer treated between January 2000 and December 2007. Statistical comparison between subgroups of patients concerning survival was carried out employing log-rank test for the invariable analysis and Cox model for the multivariable analysis. Factors included: age group (≤50 years vs. >50; ≤70 years vs. >70; ≤35 years vs. >35), menopausal status, presentation of metastatic disease (SM vs. MM), disease free interval (DFI) (≤24 months vs. >24 months; ≤60 months vs. >60 months), performance status at diagnosis of metastatic disease (PS) (0-1 vs. >1), hormone receptors (HR), number of metastatic sites (1 site vs. >1), nature of the metastatic site (visceral vs. non visceral), first line therapy, surgery of the primary tumor (SPT), locoregional radiotherapy (LRRT) and use or not of bisphosphonates. Overall survival at 5 years was 12%. Positive prognostic factors in univariate analysis were: age ≤ 70 years, hormono-dependence of the tumor, good PS (PS 0-1), less than two metastatic sites, no visceral metastases, DFI ≥ 24 months, SPT or LRRT. In multivariate analysis, favorable independent prognostic factors included: good PS (PS 0-1), absence of visceral metastases (liver, lung, brain) and age ≤ 70 years. Many of the prognostic factors in metastatic breast cancer found in our study are known in the literature but some of them, like the application of locoregional treatment (radiotherapy or surgery) and the use of bisphosphonates, need to be further investigated in randomized clinical trials.Keywords
This publication has 35 references indexed in Scilit:
- Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patientsRadiology and Oncology, 2011
- Survival differences among women with de novo stage IV and relapsed breast cancerAnnals of Oncology, 2010
- Breast Cancer With Synchronous Metastases: Survival Impact of Exclusive Locoregional RadiotherapyJournal of Clinical Oncology, 2009
- Prognostic factors in 1038 women with metastatic breast cancerAnnals of Oncology, 2008
- Clinical Course of Breast Cancer Patients With Metastases Limited to the Liver Treated With ChemotherapyThe Cancer Journal, 2008
- Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factorsAnti-Cancer Drugs, 2006
- Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 womenBreast Cancer Research and Treatment, 2005
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Breast cancer metastatic to abdomen and pelvis: role of surgical resection☆Gynecologic Oncology, 2003
- The clinical course of lung metastases from breast cancerJournal of Molecular Medicine, 1988